Amarantus Bioscience is a development-stage biotechnology company focused on developing certain biologics surrounding its intellectual property and proprietary technologies for treating and/or diagnosing Parkinson’s disease, traumatic brain injury and other human diseases. Amarantus owns the intellectual property rights to Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), a therapeutic protein, and is developing MANF-based products as treatments for brain disorders. The company is additionally a founding member of the Coalition for Concussion Treatment. For more information, visit the company’s Web site at www.Amarantus.com.

The 6th Annual OneMedForum is a gathering of leading investors and management of some of the most promising emerging life science companies in Asia and North America. Through panels, workshops and up-close programming with top industry leaders, attendees explore strategies for company growth finance with healthcare investors looking for outsized returns. For more information, please visit www.onemedforum.com.

Let us hear your thoughts below: